

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

| | |
|-----------------------------|--------------------|
| Application Number | 10/664,341 |
| Filing Date | September 16, 2003 |
| First Named Inventor | Zdanovsky, Alexey |
| Group Art Unit | 1652 |
| Examiner Name | Pak, Yong |

Sheet 1 of 1

Attorney Docket No: 341.021US1

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|----------------------|--|----------------|
| | | "European Patent Application No. 03754599.3 (Atty Ref 341.021EP1), Communication Pursuant to Article 96(2) EPC mailed 1-25-07", 4 pgs. | |
| | | "European Patent Application No. 03754599.3 (Atty Ref 341.021EP1), Communication pursuant to Article 96(2) mailed 5-22-07", 5 pgs. | |
| | | "European Patent Application No. 03754599.3 (Atty Ref 341.021EP1), Supplemental European Search Report mailed 8-4-2006", 7 pgs. | |
| | | "European Patent Application No. 03754599.3 (Atty Ref 341.021EP1), Supplemental Partial European Search Report mailed 5-17-2006", 5 pgs. | |
| | | "European Patent Application No. 03754599.3 (Atty Ref 341.023EP1), Response filed 4-20-07 to Communication mailed 1-25-07", 17 pgs. | |
| | | "PCT Application No. PCT/US03/28939 (Atty Ref 341.021WO1), International Preliminary Examination Report mailed 10-12-2006", 6 pgs. | |
| | | ADRAIN, C., et al., "Apoptosis-Associated Release of Smac/DIABLO From Mitochondria Requires Active Caspases and is Blocked by Bcl-2", <u>The EMBO Journal</u> , 20(23), (2001), 6627-6636 | |
| | | BERKERS, C. R., et al., "Activity Probe for in vivo Profiling of the Specificity of Proteasome Inhibitor Bortezomib", <u>Nature Methods</u> , 2(5), (2005), 357-362 | |
| | | FERNANDEZ, Y., et al., "Differential Regulation of Noxa in Normal Melanocytes and Melanoma Cells by Proteasome Inhibition: Therapeutic Implications", <u>Cancer Research</u> , 65(14), (2005), 6294-6304 | |
| | | KISSELEV, A. F., et al., "Importance of the Different Proteolytic Sites of the Proteasome and the Efficacy of Inhibitors Varies With Protein Substrate", <u>The Journal of Biological Chemistry</u> , 281(13), (March 31, 2006), 8582-8590 | |
| | | KISSELEV, A. F., et al., "Monitoring Activity and Inhibition of 26S Proteasomes With Fluorogenic Peptide Substrates", <u>Methods in Enzymology</u> , Vol. 398, (2005), 364-378 | |
| | | LUKER, G. D., et al., "Imaging 26S Proteasome Activity and Inhibition in Living Mice", <u>Nature Medicine</u> , 9(7), (2003), 969-973 | |
| | | RAMSBY, M. L., "Differential Detergent Fractionation of Isolated Hepatocytes: Biochemical, Immunochemical and Two-Dimensional Gel Electrophoresis Characterization of Cytoskeletal and Noncytoskeletal Compartments", <u>Electrophoresis</u> , 15, (1994), 265-277 | |
| | | WILKINSON, J. C., et al., "Upstream Regulatory Role for XIAP in Receptor-Mediated Apoptosis", <u>Molecular and Cellular Biology</u> , 24(16), (2004), 7003-7014 | |

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached